Wet Age-Related Macular Degeneration (AMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Wet Age-Related Macular Degeneration (AMD) Market Outlook
Thelansis’s “Wet Age-Related Macular
Degeneration (AMD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Wet
Age-Related Macular Degeneration (AMD) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Wet
Age-Related Macular Degeneration (AMD) Overview
Wet
Age-Related Macular Degeneration (AMD), also known as neovascular or exudative
AMD, is a progressive retinal disorder characterized by the abnormal growth of
blood vessels beneath the macula, the central portion of the retina responsible
for sharp, detailed vision. These fragile vessels tend to leak blood and fluid,
leading to macular scarring and rapid deterioration of central vision, often
manifesting as visual distortions, blind spots, or difficulty recognizing faces
and reading. Although it accounts for only 10–15% of AMD cases, wet AMD is
responsible for the majority of severe vision loss associated with the disease.
It typically evolves from the dry form of AMD and can progress swiftly if
untreated. Diagnosis relies on imaging modalities such as optical coherence
tomography (OCT) and fluorescein angiography, which help visualize fluid
accumulation and vascular changes. Treatment has advanced significantly with
intravitreal anti-VEGF therapies that inhibit vessel growth and leakage,
offering the potential to stabilize or even improve vision if initiated
promptly.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment